Abstract:Anti-angiogenic therapy represents one of the most promising treatment modalities for human cancers. However, the response to antiangiogenic therapy in gastric cancer (GC) remains dismal. To help identify new strategies for antiangiogenic therapy in GC, we evaluated miR-205-5p expression in GC tissues from TCGA database and our hospital, and its functions in angiogenesis were explored in vitro and in vivo. We investigated miR-205-5p expression and microvessel densities (MVDs) in GC tissues and liver metastases from patients. The function and mechanisms of miR-205-5p were examined in human cell lines and in xenograft mouse models. Associations between miR-205-5p expression and clinical characteristics were analyzed using either Pearson's χ2 test or Fisher's exact test. Differences in overall survival (OS) distributions were evaluated using the log-rank test. Differences in measurement data were compared using Student's t-test and one-way ANOVA. We found that miR-205-5p expression was downregulated in GC tissues and was negatively correlated with CD31 expression in both TCGA and our clinical samples. GC cell lines expressed low levels of miR-205-5p, and miR-205-5p upregulation significantly impaired the proliferation and angiogenesis of GC cells. Moreover, vascular endothelial growth factor A (VEGFA) and fibroblast growth factor 1 (FGF1) expression and activation of extracellular-related kinase (ERK) signaling were suppressed by miR-205-5p. MiR-205-5p inhibition promoted malignant phenotypes by enhancing VEGFA and FGF1 expression, as well as the activation of ERK signaling. Angiogenesis and ERK signaling were decreased in response to VEGFA and FGF1 downregulation induced by miR-205-5p overexpression. The dual-luciferase reporter assay showed that VEGFA and FGF1 were direct targets of miR-205-5p. Xenograft mouse models revealed that miR-205-5p suppressed tumor growth by inhibiting neovascularization. Altogether, these results demonstrate that miR-205-5p suppresses angiogenesis in GC by attenuating the expression of VEGFA and FGF1, indicating that upregulation of miR-205-5p may represent as an antiangiogenic therapy for GC.

MiR-205-5p Functions as a Tumor Suppressor in Gastric Cancer Cells through Downregulating FAM84B

Mir-140-3p is Involved in the Occurrence and Metastasis of Gastric Cancer by Regulating the Stability of FAM83B

Mir-338-3p Functions As a Tumor Suppressor in Gastric Cancer by Targeting PTP1B

MiR-205–5p suppresses angiogenesis in gastric cancer by downregulating the expression of VEGFA and FGF1

miR-335-5p suppresses gastric cancer progression by targeting MAPK10

MiR-1-3p Targets CENPF to Repress Tumor-Relevant Functions of Gastric Cancer Cells

MiR-301a-5p/SCIN promotes gastric cancer progression via regulating STAT3 and NF-κB signaling

MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells

MiR-378a-3p acts as a tumor suppressor in gastric cancer via directly targeting RAB31 and inhibiting the Hedgehog pathway proteins GLI1/2

MiRNA-219a-1-3p inhibits the malignant progression of gastric cancer and is regulated by DNA methylation

MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer.

Mir-137 Plays Tumor Suppressor Roles in Gastric Cancer Cell Lines by Targeting KLF12 and MYO1C

MicroRNA-501-3p targeting TM4SF1 facilitates tumor-related behaviors of gastric cancer cells via EMT signaling pathway

Mir-96-5p Enhances Cell Proliferation and Invasion Via Targeted Regulation of ZDHHC5 in Gastric Cancer

MicroRNA‐18a modulates P53 expression by targeting IRF2 in gastric cancer patients

Mir-215 Promotes Cell Migration and Invasion of Gastric Cancer by Targeting Retinoblastoma Tumor Suppressor Gene 1.

Microrna-219-2-3p Functions As A Tumor Suppressor In Gastric Cancer And Is Regulated By Dna Methylation

MiR-509-3p promotes gastric cancer development by activating FOXM1-mediated p38/MK2 pathway

MicroRNA-146a-5p induces cell cycle arrest and enhances apoptosis in gastric cancer via targeting CDC14A

Tumor Suppressor Mir-449A Inhibits the Development of Gastric Cancerviadown-Regulation of SGPL1

miR-488 acts as a tumor suppressor gene in gastric cancer